ALVR is expected to report earnings to rise 90.00% to -9 cents per share on November 29
Q3'24
Est.
$-0.09
Q2'24
Beat
by $0.04
Q1'24
Missed
by $0.02
Q4'23
Missed
by $0.05
Q3'23
Beat
by $0.03
The last earnings report on August 01 showed earnings per share of -5 cents, beating the estimate of -9 cents. With 281.58K shares outstanding, the current market capitalization sits at 52.81M.
a company, which engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases